Cargando…

Insulin: The Friend and the Foe in the Development of Type 2 Diabetes Mellitus

Insulin, a hormone produced by pancreatic β-cells, has a primary function of maintaining glucose homeostasis. Deficiencies in β-cell insulin secretion result in the development of type 1 and type 2 diabetes, metabolic disorders characterized by high levels of blood glucose. Type 2 diabetes mellitus...

Descripción completa

Detalles Bibliográficos
Autor principal: Rachdaoui, Nadia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7084909/
https://www.ncbi.nlm.nih.gov/pubmed/32150819
http://dx.doi.org/10.3390/ijms21051770
_version_ 1783508831537463296
author Rachdaoui, Nadia
author_facet Rachdaoui, Nadia
author_sort Rachdaoui, Nadia
collection PubMed
description Insulin, a hormone produced by pancreatic β-cells, has a primary function of maintaining glucose homeostasis. Deficiencies in β-cell insulin secretion result in the development of type 1 and type 2 diabetes, metabolic disorders characterized by high levels of blood glucose. Type 2 diabetes mellitus (T2DM) is characterized by the presence of peripheral insulin resistance in tissues such as skeletal muscle, adipose tissue and liver and develops when β-cells fail to compensate for the peripheral insulin resistance. Insulin resistance triggers a rise in insulin demand and leads to β-cell compensation by increasing both β-cell mass and insulin secretion and leads to the development of hyperinsulinemia. In a vicious cycle, hyperinsulinemia exacerbates the metabolic dysregulations that lead to β-cell failure and the development of T2DM. Insulin and IGF-1 signaling pathways play critical roles in maintaining the differentiated phenotype of β-cells. The autocrine actions of secreted insulin on β-cells is still controversial; work by us and others has shown positive and negative actions by insulin on β-cells. We discuss findings that support the concept of an autocrine action of secreted insulin on β-cells. The hypothesis of whether, during the development of T2DM, secreted insulin initially acts as a friend and contributes to β-cell compensation and then, at a later stage, becomes a foe and contributes to β-cell decompensation will be discussed.
format Online
Article
Text
id pubmed-7084909
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70849092020-03-23 Insulin: The Friend and the Foe in the Development of Type 2 Diabetes Mellitus Rachdaoui, Nadia Int J Mol Sci Review Insulin, a hormone produced by pancreatic β-cells, has a primary function of maintaining glucose homeostasis. Deficiencies in β-cell insulin secretion result in the development of type 1 and type 2 diabetes, metabolic disorders characterized by high levels of blood glucose. Type 2 diabetes mellitus (T2DM) is characterized by the presence of peripheral insulin resistance in tissues such as skeletal muscle, adipose tissue and liver and develops when β-cells fail to compensate for the peripheral insulin resistance. Insulin resistance triggers a rise in insulin demand and leads to β-cell compensation by increasing both β-cell mass and insulin secretion and leads to the development of hyperinsulinemia. In a vicious cycle, hyperinsulinemia exacerbates the metabolic dysregulations that lead to β-cell failure and the development of T2DM. Insulin and IGF-1 signaling pathways play critical roles in maintaining the differentiated phenotype of β-cells. The autocrine actions of secreted insulin on β-cells is still controversial; work by us and others has shown positive and negative actions by insulin on β-cells. We discuss findings that support the concept of an autocrine action of secreted insulin on β-cells. The hypothesis of whether, during the development of T2DM, secreted insulin initially acts as a friend and contributes to β-cell compensation and then, at a later stage, becomes a foe and contributes to β-cell decompensation will be discussed. MDPI 2020-03-05 /pmc/articles/PMC7084909/ /pubmed/32150819 http://dx.doi.org/10.3390/ijms21051770 Text en © 2020 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Rachdaoui, Nadia
Insulin: The Friend and the Foe in the Development of Type 2 Diabetes Mellitus
title Insulin: The Friend and the Foe in the Development of Type 2 Diabetes Mellitus
title_full Insulin: The Friend and the Foe in the Development of Type 2 Diabetes Mellitus
title_fullStr Insulin: The Friend and the Foe in the Development of Type 2 Diabetes Mellitus
title_full_unstemmed Insulin: The Friend and the Foe in the Development of Type 2 Diabetes Mellitus
title_short Insulin: The Friend and the Foe in the Development of Type 2 Diabetes Mellitus
title_sort insulin: the friend and the foe in the development of type 2 diabetes mellitus
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7084909/
https://www.ncbi.nlm.nih.gov/pubmed/32150819
http://dx.doi.org/10.3390/ijms21051770
work_keys_str_mv AT rachdaouinadia insulinthefriendandthefoeinthedevelopmentoftype2diabetesmellitus